ANTI-TIGIT/ANTI-PVRIG BISPECIFIC ANTIBODY, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
The present invention belongs to the field of biological medicines, and relates to an anti-TIGIT/anti-PVRIG bispecific antibody, and a pharmaceutical composition and use thereof. Specifically, the present invention relates to a bispecific antibody, comprising: a first protein functional region targe...
Gespeichert in:
| Hauptverfasser: | , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | DAI, Shuang MIAO, Xiaoniu HUANG, Weifeng TSUN, Andy ZHAI, Tianhang |
| description | The present invention belongs to the field of biological medicines, and relates to an anti-TIGIT/anti-PVRIG bispecific antibody, and a pharmaceutical composition and use thereof. Specifically, the present invention relates to a bispecific antibody, comprising: a first protein functional region targeting PVRIG and a second protein functional region targeting a target (e.g., TIGIT) different from PVRIG, wherein the first protein functional region is an anti-PVRIG immunoglobulin or an antigen-binding fragment thereof; a heavy chain variable region of the anti-PVRIG immunoglobulin comprises HCDR1 having an amino acid sequence as set forth in SEQ ID NO: 25, HCDR2 having an amino acid sequence as set forth in SEQ ID NO: 26, and HCDR3 having an amino acid sequence as set forth in SEQ ID NO: 27; and a light chain variable region of the anti-PVRIG immunoglobulin comprises LCDR1 having an amino acid sequence as set forth in SEQ ID NO: 22, LCDR2 having an amino acid sequence as set forth in SEQ ID NO: 23, and LCDR3 having an amino acid sequence as set forth in SEQ ID NO: 24. The bispecific antibody of the present invention has a good anti-tumor effect. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_AU2023247712A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>AU2023247712A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_AU2023247712A13</originalsourceid><addsrcrecordid>eNrjZIh09Avx1A3xdPcM0QczA8KCPN0VnDyDA1ydPd08nRVAok7-LpE6QJaLQoCHY5Cvo7NraIins6OPgrO_b4B_sGeIp78fWDo02FUhxMM1yNXfjYeBNS0xpziVF0pzMyi7uYY4e-imFuTHpxYXJCan5qWWxDuGGhkYGRuZmJsbGjkaGhOnCgDhODJE</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>ANTI-TIGIT/ANTI-PVRIG BISPECIFIC ANTIBODY, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF</title><source>esp@cenet</source><creator>DAI, Shuang ; MIAO, Xiaoniu ; HUANG, Weifeng ; TSUN, Andy ; ZHAI, Tianhang</creator><creatorcontrib>DAI, Shuang ; MIAO, Xiaoniu ; HUANG, Weifeng ; TSUN, Andy ; ZHAI, Tianhang</creatorcontrib><description>The present invention belongs to the field of biological medicines, and relates to an anti-TIGIT/anti-PVRIG bispecific antibody, and a pharmaceutical composition and use thereof. Specifically, the present invention relates to a bispecific antibody, comprising: a first protein functional region targeting PVRIG and a second protein functional region targeting a target (e.g., TIGIT) different from PVRIG, wherein the first protein functional region is an anti-PVRIG immunoglobulin or an antigen-binding fragment thereof; a heavy chain variable region of the anti-PVRIG immunoglobulin comprises HCDR1 having an amino acid sequence as set forth in SEQ ID NO: 25, HCDR2 having an amino acid sequence as set forth in SEQ ID NO: 26, and HCDR3 having an amino acid sequence as set forth in SEQ ID NO: 27; and a light chain variable region of the anti-PVRIG immunoglobulin comprises LCDR1 having an amino acid sequence as set forth in SEQ ID NO: 22, LCDR2 having an amino acid sequence as set forth in SEQ ID NO: 23, and LCDR3 having an amino acid sequence as set forth in SEQ ID NO: 24. The bispecific antibody of the present invention has a good anti-tumor effect.</description><language>eng</language><subject>BEER ; BIOCHEMISTRY ; CHEMISTRY ; COMPOSITIONS THEREOF ; CULTURE MEDIA ; ENZYMOLOGY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; MICROBIOLOGY ; MICROORGANISMS OR ENZYMES ; MUTATION OR GENETIC ENGINEERING ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS ; SPIRITS ; VINEGAR ; WINE</subject><creationdate>2024</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20241031&DB=EPODOC&CC=AU&NR=2023247712A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76516</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20241031&DB=EPODOC&CC=AU&NR=2023247712A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>DAI, Shuang</creatorcontrib><creatorcontrib>MIAO, Xiaoniu</creatorcontrib><creatorcontrib>HUANG, Weifeng</creatorcontrib><creatorcontrib>TSUN, Andy</creatorcontrib><creatorcontrib>ZHAI, Tianhang</creatorcontrib><title>ANTI-TIGIT/ANTI-PVRIG BISPECIFIC ANTIBODY, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF</title><description>The present invention belongs to the field of biological medicines, and relates to an anti-TIGIT/anti-PVRIG bispecific antibody, and a pharmaceutical composition and use thereof. Specifically, the present invention relates to a bispecific antibody, comprising: a first protein functional region targeting PVRIG and a second protein functional region targeting a target (e.g., TIGIT) different from PVRIG, wherein the first protein functional region is an anti-PVRIG immunoglobulin or an antigen-binding fragment thereof; a heavy chain variable region of the anti-PVRIG immunoglobulin comprises HCDR1 having an amino acid sequence as set forth in SEQ ID NO: 25, HCDR2 having an amino acid sequence as set forth in SEQ ID NO: 26, and HCDR3 having an amino acid sequence as set forth in SEQ ID NO: 27; and a light chain variable region of the anti-PVRIG immunoglobulin comprises LCDR1 having an amino acid sequence as set forth in SEQ ID NO: 22, LCDR2 having an amino acid sequence as set forth in SEQ ID NO: 23, and LCDR3 having an amino acid sequence as set forth in SEQ ID NO: 24. The bispecific antibody of the present invention has a good anti-tumor effect.</description><subject>BEER</subject><subject>BIOCHEMISTRY</subject><subject>CHEMISTRY</subject><subject>COMPOSITIONS THEREOF</subject><subject>CULTURE MEDIA</subject><subject>ENZYMOLOGY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>MICROBIOLOGY</subject><subject>MICROORGANISMS OR ENZYMES</subject><subject>MUTATION OR GENETIC ENGINEERING</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><subject>SPIRITS</subject><subject>VINEGAR</subject><subject>WINE</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2024</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZIh09Avx1A3xdPcM0QczA8KCPN0VnDyDA1ydPd08nRVAok7-LpE6QJaLQoCHY5Cvo7NraIins6OPgrO_b4B_sGeIp78fWDo02FUhxMM1yNXfjYeBNS0xpziVF0pzMyi7uYY4e-imFuTHpxYXJCan5qWWxDuGGhkYGRuZmJsbGjkaGhOnCgDhODJE</recordid><startdate>20241031</startdate><enddate>20241031</enddate><creator>DAI, Shuang</creator><creator>MIAO, Xiaoniu</creator><creator>HUANG, Weifeng</creator><creator>TSUN, Andy</creator><creator>ZHAI, Tianhang</creator><scope>EVB</scope></search><sort><creationdate>20241031</creationdate><title>ANTI-TIGIT/ANTI-PVRIG BISPECIFIC ANTIBODY, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF</title><author>DAI, Shuang ; MIAO, Xiaoniu ; HUANG, Weifeng ; TSUN, Andy ; ZHAI, Tianhang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_AU2023247712A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2024</creationdate><topic>BEER</topic><topic>BIOCHEMISTRY</topic><topic>CHEMISTRY</topic><topic>COMPOSITIONS THEREOF</topic><topic>CULTURE MEDIA</topic><topic>ENZYMOLOGY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>MICROBIOLOGY</topic><topic>MICROORGANISMS OR ENZYMES</topic><topic>MUTATION OR GENETIC ENGINEERING</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><topic>SPIRITS</topic><topic>VINEGAR</topic><topic>WINE</topic><toplevel>online_resources</toplevel><creatorcontrib>DAI, Shuang</creatorcontrib><creatorcontrib>MIAO, Xiaoniu</creatorcontrib><creatorcontrib>HUANG, Weifeng</creatorcontrib><creatorcontrib>TSUN, Andy</creatorcontrib><creatorcontrib>ZHAI, Tianhang</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>DAI, Shuang</au><au>MIAO, Xiaoniu</au><au>HUANG, Weifeng</au><au>TSUN, Andy</au><au>ZHAI, Tianhang</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>ANTI-TIGIT/ANTI-PVRIG BISPECIFIC ANTIBODY, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF</title><date>2024-10-31</date><risdate>2024</risdate><abstract>The present invention belongs to the field of biological medicines, and relates to an anti-TIGIT/anti-PVRIG bispecific antibody, and a pharmaceutical composition and use thereof. Specifically, the present invention relates to a bispecific antibody, comprising: a first protein functional region targeting PVRIG and a second protein functional region targeting a target (e.g., TIGIT) different from PVRIG, wherein the first protein functional region is an anti-PVRIG immunoglobulin or an antigen-binding fragment thereof; a heavy chain variable region of the anti-PVRIG immunoglobulin comprises HCDR1 having an amino acid sequence as set forth in SEQ ID NO: 25, HCDR2 having an amino acid sequence as set forth in SEQ ID NO: 26, and HCDR3 having an amino acid sequence as set forth in SEQ ID NO: 27; and a light chain variable region of the anti-PVRIG immunoglobulin comprises LCDR1 having an amino acid sequence as set forth in SEQ ID NO: 22, LCDR2 having an amino acid sequence as set forth in SEQ ID NO: 23, and LCDR3 having an amino acid sequence as set forth in SEQ ID NO: 24. The bispecific antibody of the present invention has a good anti-tumor effect.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng |
| recordid | cdi_epo_espacenet_AU2023247712A1 |
| source | esp@cenet |
| subjects | BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS VINEGAR WINE |
| title | ANTI-TIGIT/ANTI-PVRIG BISPECIFIC ANTIBODY, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-15T00%3A14%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=DAI,%20Shuang&rft.date=2024-10-31&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EAU2023247712A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |